Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD
Published: Tuesday, Dec 12, 2017



Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

In 2017, the FDA approved nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), and pembrolizumab (Keytruda) for the second-line treatment of patients with bladder cancer. These drugs join previously approved atezolizumab (Tecentriq).

It is hard to differentiate between these 5 regimens, says Plimack, as there are no randomized trials comparing them in this setting.
 
SELECTED
LANGUAGE


Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

In 2017, the FDA approved nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), and pembrolizumab (Keytruda) for the second-line treatment of patients with bladder cancer. These drugs join previously approved atezolizumab (Tecentriq).

It is hard to differentiate between these 5 regimens, says Plimack, as there are no randomized trials comparing them in this setting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x